New hope for tough breast cancer: testing combo therapy
NCT ID NCT05227664
Summary
This study is testing whether adding two new drugs, AK117 and AK112, to standard chemotherapy works better for people with advanced triple-negative breast cancer that has spread. It will involve about 120 patients who have not yet received treatment for their advanced cancer. The main goals are to see if the combination shrinks tumors effectively and is safe for patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hunan Cancer Hospital
Changsha, China
-
Xiangyang Central Hospital
Xiangyang, China
Conditions
Explore the condition pages connected to this study.